Monoclonal Antibody treatment means a biological therapy where monoclonal antibodies is used to initiate development of specific antibodies (protein molecules produced by the B cells as a primary immune defense), so that they can fight against antigens (substances that are capable of inducing a specif...
The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and ...
Threonine phosphorylation accounts for 10% of all phosphorylation sites compared with 0.05% for tyrosine and 90% for serine. Although monoclonal antibody generation for phospho-serine and -tyrosine proteins is progressing, there has been limited success
Sherman WH, Latov N, Hays AP, et al. Monoclonal IgM kappa antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis. Neurology. 1983;33(2):192–201. ArticlePubMedCASGoogle Scholar Freddo L, Sherman WH, Latov N. Glycosaminoglycan antigens in per...
ALPP monoclonal antibody, clone SPM593, MAB13052, highly specific and rigorously validated in-house for Immunohistochemistry (IHC), Immunocytochemistry (ICC/IF), Flow Cytometry (Flow). Reacts with Human.ALPP monoclonal antibody, clone SPM593, MAB13052 is
One monoclonal antibody to ClfA called aurexis showed great promise in animal models for the treatment of staphylococcal infections. However, in a limited phase II clinical trial the efficacy was less impressive. We have solved the structure of the Fab fragment of tefibazumab (the humanized ...
In order to identify the fine specificity of anti-CHIKV antibody response, Kam et al. performed a longitudinal analysis of human antibody response against distinct viral proteins using plasma from patients collected at various points following infection. They discovered proteins such as E2, E3, capsi...
Although monoclonal antibody generation for phospho-serine and -tyrosine proteins is progressing, there has been limited success regarding the production of monoclonal antibodies against phospho-threonine proteins. We developed a novel strategy for generating phosphorylation site-specific monoclonal antibodies ...